Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's Kaletra Promotions Overstate Length Of Efficacy, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

A poster and print ad for the protease inhibitor combo make the unsubstantiated claim that patients taking Kaletra "can expect to survive and be healthy" for five years, FDA says. Abbott releases six-year Kaletra data at ICAAC conference.

You may also be interested in...



Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter

Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.

Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter

Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.

Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price

Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel